Condition
Knee Osteoarthritis: Options and What the Evidence Actually Shows
The highest-intent regenerative search. Here is the care ladder, the trial record on same-day products, and why dose and donor age reframes the category.
Anatomy and clinical context
Knee OA is progressive cartilage loss with bone remodeling, synovitis, and pain that fluctuates with load. Severity on X-ray does not always match symptoms.
Guidelines emphasize exercise, weight loss when relevant, and education before procedures. Injections and arthroplasty fill later rungs.
Illustration of the human knee joint
The standard-of-care ladder
Conservative care first, then injections, then surgery when indicated. Cell therapy belongs in that conversation — not above it.
- Step 1
Conservative care
Exercise therapy, weight management, bracing, and oral meds.
- Step 2
Injections
Corticosteroid, hyaluronic acid, PRP, BMAC/SVF and related orthobiologics when physician-directed.
- Step 3
Surgery
Osteotomy or partial/total knee arthroplasty for advanced disease.
Where cell therapy fits
Knee OA has the clearest controlled-trial record for same-day orthobiologics — and that record often shows parity, not superiority, versus steroid or saline. Expanded-cell products tell a different dose story.
- MILES (n=440): BMAC, umbilical tissue, and SVF did not beat corticosteroid at one year; MRI did not improve.
- Shapiro 2017: BMAC vs saline in the contralateral knee — no difference.
- Culture-expanded approvals abroad (e.g. Cartistem) show what therapeutic dose can look like when manufacturing exists.
Selected citations
MILES
Mautner et al. · Nature Medicine (2023)
n=440 knee OA trial: BMAC, umbilical tissue, and SVF vs corticosteroid — none beat steroid at one year; none moved MRI scores.
Shapiro 2017
Shapiro et al. · AJSM (2017)
BMAC vs saline in the same patient's other knee — no difference on primary outcomes.
Cartistem
Approved product (Korea) · Regulatory approval (2012)
Culture-expanded allogeneic MSC product approved in Korea with structural signal in cartilage repair settings.
Stempeucel
Approved product (India) · Regulatory approval (2020)
Culture-expanded MSC product approved in India — example of dose-enabled products showing clinical pathway beyond same-day unexpanded injectates.
Why dose and donor age change the picture
The trials that disappoint used unexpanded cells from older donors.
The ones that work used expanded cells at therapeutic dose. Dose is the variable — and dose is what expansion buys you. Potency is what your age buys you.
- 1
Cells work at dose.
A same-day draw yields a small, uncounted, unexpanded fraction. Expansion turns one draw into many doses.
- 2
Potency is age-dependent, and it is a one-way door.
Your MSCs at 35 are not your MSCs at 55. Banking is the only mechanism that makes 35-year-old cells available to a 55-year-old.
- 3
Expansion is what makes the bank a supply, not a souvenir.
Bank once, expand repeatedly, across a treatment course rather than a single shot. Culture expansion for Forever Labs members is rolling out — starting with selected states as our Florida cGMP lab comes online.
- 4
The provider decides what happens next.
We supply cells; they practice medicine. Forever Labs does not treat conditions — your physician owns the clinical relationship.
Two next steps — equal weight
Forever Labs does not treat conditions. Your physician owns the clinical relationship. We bank cells and, as expansion rolls out, help make dose possible.